Felix Feng, MD, discusses results from exploratory analysis of the phase 3 SPARTAN trial, which investigated potential biological signatures of patients with nonmetastatic CRPC who achieved long-term responses to apalutamide and placebo.
Hala Borno, MD, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.